Explore our library of blogs, insights, research papers, and more information on compliance in the life sciences industry.
A few weeks ago, as we briefly covered news on Insys Therapeutics, we realized that the ripples of its scandal would be felt across the pond. And indeed, qordata finds many compliance professionals in the EU pharma industry voicing concerns about the possibility of something like this happening in their own markets. The fact that […]
There’s a reason business lingo has so much of what I would call ‘war words’: Starting with the all-famous “strategy”, to “target”, “guerilla tactics,” “mission,” “red ocean” and so on. The way I see it, the reason is that in war as in business, rivals compete ruthlessly for the same reward in a challenging and […]
In the American medical drug and device industry, poor compliance practices never go away. They keep coming back to haunt you in newer and more alarming ways. Take Insys Therapeutics, Inc. In less than three years, it has gained infamy for using unethical means (read: violation of good pharmaceutical compliance practices) to sell its opioid, […]
Samuel D. Warren and Louis D. Brandeis’ 1890 article “The Right To Privacy” has become classic reading for 21st century data professionals. But as we discovered in an excellent webinar with Denise Farnsworth Chief Privacy Officer, and Senior Corporate Counsel at Jazz Pharmaceuticals, Brandeis’ article forms only half of the data privacy story. What data […]
The approach towards data privacy in the EU makes consideration towards consent revocation an imperative. If a physician revokes consent, individual versus aggregate spend figures need to be recalculated, and they will show the corresponding changes. Thus, historical consent rate figures may not be an accurate indicator of transparency in that specific market or even […]
Physician consent can be a contentious issue. Especially when data privacy interpretation comes into play. In a webinar we hosted, Brian Sharkey, VP of Porzio Life Sciences LLC, raised a question about the validity of consent rates as an indicator of pharmaceutical transparency. So, is there a direct correlation between transparency in the pharmaceutical sector […]
Your usage of this site constitutes acceptance of our Terms of Use & Data Policy. The material on this say may not be reproduced, distributed, transmitted, cached, or otherwise used without qordata’s consent. qordata is an Equal Opportunity Employer. All qualified individuals are accepted as employees and will receive consideration for employment without regard to race, gender, color, age, religion, sex, national origin, protected veteran status, or any other characteristic protected under federal, state, or local law.
© qordata 2024. All rights reserved | Sitemap | Privacy Policy | Terms of Use